clinical trial · NCT06828354
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.·phase3·recruiting·n = 300
Ovarian CancerSHR-A1811Paclitaxel InjectionDoxorubicin Hydrochloride Liposome InjectionGemcitabine Hydrochloride for InjectionTopotecan Hydrochloride for Injection
brief summary
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
started
Mar 13, 2025
primary completion
May 1, 2027
completion
Dec 1, 2027
last updated
Apr 20, 2026
official title
An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol